Quick Answer
Ultragenyx Pharmaceutical Inc. reported Earnings Per Share Diluted of $5.83 (loss) per share for the year ending 2025.
- Ultragenyx Pharmaceutical Inc. showed an increase of +7.3% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Ultragenyx Pharmaceutical Inc.'s annual report (Form 10-K), filed with the SEC on February 18, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 6 years of available data (2020 to 2025), Ultragenyx Pharmaceutical Inc.'s Earnings Per Share Diluted has declined by 89.9%.
- Historical annual values: Fiscal year 2025: $5.83 (loss) per share | Fiscal year 2024: $6.29 (loss) per share | Fiscal year 2023: $8.25 (loss) per share | Fiscal year 2022: $10.12 (loss) per share | Fiscal year 2021: $6.70 (loss) per share | Fiscal year 2020: $3.07 (loss) per share.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: